Amit G Pandya MD

Professor, Dermatology, University of Texas Southwestern Medical Center, Southwestern Medical School

701 E El Camino RealMountain View, CA 94040
Phone+1 650-934-7676
Fax+1 408-735-7297

Dr. Pandya is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pandya's full profile Already have an account?

Education & Training

University of Texas Southwestern Medical CenterResidency, Dermatology, 1988 - 1991
Texas Health Resources (Dallas)Residency, Internal Medicine, 1985 - 1988
University of Texas Southwestern Medical SchoolClass of 1985

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2019 - 2027
TX State Medical License 1986 - 2023
American Board of Dermatology Dermatology
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2017
Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris
TERMINATED
PHASE2
Use of KC706 for the Treatment of Pemphigus Vulgaris
COMPLETED
PHASE2
Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis
TERMINATED
NA

Publications & Presentations

PubMed

Assessment of vitiligo in clinical practice: a cross-sectional survey among experts.
Jolien Duponselle, Marlide R Jukema, Albert Wolkerstorfer, Khaled Ezzedine, Iltefat Hamzavi
The Journal of Dermatological Treatment. 2025-12-01
Autologous cell harvesting device provides repigmentation and improves quality-of-life for patients with stable vitiligo lesions in a large and diverse patient populat...
Amit G Pandya, Bassel H Mahmoud, Richard H Huggins, Anand K Ganesan, Nanette B Silverberg
Journal of the American Academy of Dermatology. 2025-08-01
3 citations
Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies.
Julien Seneschal, Albert Wolkerstorfer, Seemal R Desai, Pearl Grimes, Khaled Ezzedine
Dermatology and Therapy. 2025-05-01

Journal Articles

International Initiative for Outcomes (INFO) for Vitiligo: Workshops with Vitiligo Patients on Repigmentation
A Pandya, J E Harris, N Elbuluk, The British Journal of Dermatology

Lectures

Skin of Color
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/1/2019
Closing the Gender Gap in Academic Dermatology and Dermatology Leadership: Problems and Solutions
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/4/2019

Press Mentions

Povorcitinib Leads to Substantial Repigmentation in Nonsegmental VitiligoJune 26th, 2025
SPF Is Only the Start When Recommending SunscreensJune 2nd, 2023
Incyte Announces Positive 52-Week Results from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with VitiligoOctober 12th, 2019